x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Astbury, CarolineRemove Astbury, Caroline filter
- Watson, Michael SRemove Watson, Michael S filter
- Esplin, Edward DRemove Esplin, Edward D filter
- laboratory-developed testsRemove laboratory-developed tests filter
Publication Date
Please choose a date range between 2020 and 2020.
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
1 Results
- ACMG StatementOpen Archive
Risk categorization for oversight of laboratory-developed tests for inherited conditions: an updated position statement of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 22Issue 6p983–985Published in issue: June, 2020- Sarah T. South
- Michelle McClure
- Caroline Astbury
- Michael T. Bashford
- Judith Benkendorf
- Edward D. Esplin
- and others
Cited in Scopus: 0This document represents an update to the proposed approach of the American College of Medical Genetics and Genomics (ACMG) to categorize laboratory-developed tests (LDTs) for inherited conditions according to risk.1 Risk classification has historically been a determinant of whether, and to what extent, the US Food and Drug Administration (FDA) has overseen and regulated clinical tests. LDTs for constitutional variants continue to proliferate without a comprehensive federal regulatory framework in place.
